Moderna Cancer Vaccine Shows Melanoma Results in Phase 3, But Key Data Remains Unreleased
Moderna and Merck's intismeran Phase 3 melanoma trial met its primary endpoint, sending the stock more than doubling. But the companies have not released absolute efficacy numbers, confidence intervals, or peer-reviewed data
Follow